Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $5.00. The company’s shares closed yesterday at $1.49. El ...

After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

Investing.com - Leerink Partners has lowered its price target on iTeos Therapeutics (NASDAQ: ITOS) to $10.00 from $12.00 while maintaining a Market Perform rating on the stock.

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger ...

ITeos Therapeutics, Inc. (NASDAQ:iTOS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held iTeos Therapeutics, Inc. (NASDAQ:ITOS) at the ...

WATERTOWN, Mass. – iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company with a market capitalization of $326 million, announced today its plan to cease operations and ...